Can Ozempic Treat Alcoholism? Here’s What You Should Know
GLP-1 medications like semaglutide, initially developed for diabetes and obesity, are being explored for their potential to treat alcohol addiction. Recent studies indicate that these drugs may help reduce cravings for alcohol and other substances. Ongoing research aims to further understand their effectiveness and mechanisms in treating various substance use disorders.
- ▪Semaglutide is the active ingredient in Ozempic and Wegovy, which are popular medications for diabetes and obesity.
- ▪A recent study published in The Lancet found that participants on semaglutide consumed less alcohol compared to those on a placebo.
- ▪Researchers are investigating the potential of GLP-1s to treat other substance use disorders, including opioids and smoking.
2 outlets in our directory ran this story, first to last over 30 hours. All of the coverage we found sits in one bucket: right. That one-sidedness is itself worth noticing.
Gizmodo files mainly under tech. We currently carry 536 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Gizmodo |
| Canonical URL | https://gizmodo.com/can-ozempic-treat-alcoholism-heres-what-you-should-know-2000764479 |
| Publication time | Fri, 29 May 2026 10:00:22 +0000 |
| Retrieval time | 2026-05-29T10:05:00.327Z |
| Last seen | 2026-05-29T10:05:00.327Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | ncsBqH-2tW7N · 2 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Semaglutide (the active ingredient in Ozempic and Wegovy) and other GLP-1 medications have rapidly become some of the most popular drugs in the world. Originally developed for type 2 diabetes, GLP-1s are now better known for treating obesity. In the near future, though, these drugs could have yet another vital use as treatments for alcohol addiction and other substance use…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Gizmodo.
Discussion
0 commentsMore from Gizmodo
